Browse All

Current Filters

CLEAR FILTER x

TITLE

Continuous Ofatumumab Treatment Up to 7 Years Shows a Consistent Safety Profile and Delays Disability Progression in People with Relapsing Multiple Sclerosis

Efficacy and Safety of a Modified Ublituximab Regimen (ENHANCE)